If you are a member of PGRN.org you can apply to feature your PGx related research project on this site.
If you are a member of PGRN.org you can apply to feature your PGx related research project on this site.
On January 18th-19th 2017, the PGRN-RIKEN Meeting was held in Yokohama, Japan. The meeting brought together researchers from the US, and Japan, as well as other countries, to discuss PGRN-RIKEN collaboration research<http://www.pgrn.org/riken-projects.html> results. Before the PGRN-RIKEN meeting, PGRN members were invited to submit proposals for RIKEN to perform either targeted sequencing or genome wide genotyping on their DNA samples from pharmacogenomics studies of well-phenotypes patients. The proposals were rigorously peer-reviewed by Principal Investigators of the PGRN-RIKEN collaboration<http://www.pgrn.org/riken-investigators.html>. Only top scored projects were selected for genomewide genotyping or targeted sequencing. At the meeting, three new proposals were considered for genotyping. In addition four investigators presented research in progress of PGRN-RIKEN collaborative research studies. Finally, invited speakers included: Dr. Kazuhiko Yamamoto<http://www.riken.jp/en/research/labs/ims/autoimmun_dis/>, from RIKEN Institute, who gave an overview of functional genetics of autoimmune diseases; Dr. Henk-Jan Guchelaar, from Leiden University Medical Center, who gave an overview on the design and implementation strategy of the Ubiquitous Pharmacogenomics Consortium; and Dr. Mark Ratain<>, co-Leader of the PGRN-RIKEN collaboration, who presented the University of Chicago's experience with preemptive pharmacogenomics, the “1200 Patients Project." The PGRN-RIKEN group meets twice a year, alternating between San Francisco and Tokyo. We will keep you posted here about submitting proposals for the next meeting in San Francisco
|